high mobility group box 1 pseudogene 35Genealiases: []
Q-omics provides the consensus-scored HMGB1P35 profile across patient tissues and cancer cell-line models. HMGB1P35 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, HMGB1P35 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, HMGB1P35 RNA expression shows 6,288 significant pathway-activity associations, with the highest sampling consensus in THCA. Together, these results highlight PAAD, BRCA, and THCA as cancer lineages where HMGB1P35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB1P35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB1P35 survival associations across molecular data types. HMGB1P35 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB1P35 RNA expression–survival associations across cancer types. High HMGB1P35 expression shows unfavorable associations in LUSC, THYM, UVM, SKCM and PRAD, but favorable associations in PAAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify PAAD as the clearest survival context for HMGB1P35 RNA expression.
This table summarizes HMGB1P35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB1P35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB1P35 shows lower tumor expression in BRCA and THCA and higher tumor expression in STAD. The BRCA box plot shows higher HMGB1P35 RNA expression in normal versus tumor tissue (log2 FC = −0.045, t-test p < 0.001).
This table shows molecular features associated with HMGB1P35 in patient tissues and cancer cell lines. In patient samples, HMGB1P35 shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set.
